- Market Realist•3 hours ago
On January 27, 2012, the FDA approved Pfizer’s (PFE) Inlyta as a second-line therapy for patients suffering from advanced kidney cancer or RCC.
- Market Realist•4 hours ago
On August 26, 2011, the FDA approved Pfizer’s (PFE) Xalkori for patients suffering from late-stage NSCLC and who express abnormal ALK gene.
Pfizer Inc. (PFE)
NYSE - NYSE Real Time Price. Currency in USD
|Bid||32.60 x 9100|
|Ask||32.61 x 9800|
|Day's Range||32.37 - 32.81|
|52wk Range||28.25 - 37.39|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||28.89|
|Avg Vol (3m)||19,154,563|
|Dividend & Yield||1.20 (3.72%)|